Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect

Investigational New Drugs

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Dickinson, Michael ^a,b   Johnstone, Ricky W ^a,b   Prince, H Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Histone deacetylase inhibitor; Mechanism of action

Indexed keywords

BELINOSTAT; BUTYRIC ACID; DEATH RECEPTOR 5; ENTINOSTAT; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MOCETINOSTAT; PANOBINOSTAT; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; STAT3 PROTEIN; STAT6 PROTEIN; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CELLULAR STRESS RESPONSE; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DNA DAMAGE; DRUG EFFICACY; DRUG TARGETING; ENDOPLASMIC RETICULUM STRESS; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UNFOLDED PROTEIN RESPONSE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; PROTEIN FOLDING; TUMOR MICROENVIRONMENT;

EID: 78651352243     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-010-9596-y     Document Type: Article

References (220)

1. VM Richon TW Sandhoff RA Rifkind PA Marks 2000 Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci USA 97 18 10014 10019 1:CAS:528: DC%2BD3cXmtlehsL4%3D 10954755 10.1073/pnas.180316197
2. SY Archer S Meng A Shei RA Hodin 1998 p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells Proc Natl Acad Sci USA 95 12 6791 6796 1:CAS:528:DyaK1cXjslynur8%3D 9618491 10.1073/pnas.95.12.6791 (Pubitemid 28278059)
3. Y Sasakawa Y Naoe T Inoue T Sasakawa M Matsuo T Manda S Mutoh 2002 Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo Biochem Pharmacol 64 7 1079 1090 1:CAS:528:DC%2BD38XntVWqsLs%3D 12234611 10.1016/S0006-2952(02)01261-3 (Pubitemid 35247815)
4. Y Shao Z Gao PA Marks X Jiang 2004 Apoptotic and autophagic cell death induced by histone deacetylase inhibitors Proc Natl Acad Sci USA 101 52 18030 18035 10.1073/pnas.0408345102 1:CAS:528:DC%2BD2MXjsl2nsQ%3D%3D 15596714 10.1073/pnas.0408345102 (Pubitemid 40054069)
5. JS Carew ST Nawrocki CN Kahue H Zhang C Yang L Chung JA Houghton P Huang FJ Giles JL Cleveland 2007 Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance Blood 110 1 313 322 1:CAS:528:DC%2BD2sXnsVaitrw%3D 17363733 10.1182/blood-2006-10-050260 (Pubitemid 47026849)
6. AJM de Ruijter AH van Gennip HN Caron S Kemp ABP van Kuilenburg 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem J 370 Pt 3 737 749 10.1042/BJ20021321 12429021 (Pubitemid 36399066)
7. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev 5 9 769 784 1:CAS:528:DC%2BD28XptVCltrY%3D 10.1038/nrd2133 (Pubitemid 44348499)
8. OM Dovey CT Foster SM Cowley 2010 Emphasizing the positive: a role for histone deacetylases in transcriptional activation Cell Cycle 9 14 2700 2701 1:CAS:528:DC%2BC3cXhsFCnt7nF 20647764 10.4161/cc.9.14.12626
9. Z Wang C Zang K Cui D Schones A Barski W Peng K Zhao 2009 Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes Cell 10.1016/j.cell.2009.06.049
10. P Bertrand 2010 Inside HDAC with HDAC inhibitors Eur J Med Chem 10.1016/j.ejmech.2010.02.030 20223566
11. C Boyault K Sadoul M Pabion S Khochbin 2007 HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination Oncogene 26 37 5468 5476 10.1038/sj.onc.1210614 1:CAS:528:DC%2BD2sXovFersrw%3D 17694087 10.1038/sj.onc.1210614 (Pubitemid 47255928)
12. C Hubbert A Guardiola R Shao Y Kawaguchi A Ito A Nixon M Yoshida X-F Wang T-P Yao 2002 HDAC6 is a microtubule-associated deacetylase Nature 417 6887 455 458 10.1038/417455a 1:CAS:528:DC%2BD38XjvVersr4%3D 12024216 10.1038/417455a (Pubitemid 34563539)
13. SH Kaufmann DP Steensma 2005 On the TRAIL of a new therapy for leukemia Leukemia 19 12 2195 2202 10.1038/sj.leu.2403946 1:CAS:528:DC%2BD2MXht1ems7nN 16224489 10.1038/sj.leu.2403946 (Pubitemid 41741614)
14. A Insinga S Monestiroli S Ronzoni V Gelmetti F Marchesi A Viale L Altucci C Nervi S Minucci PG Pelicci 2005 Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway Nat Med 11 1 71 76 10.1038/nm1160 1:CAS:528:DC%2BD2MXovF2m 15619634 10.1038/nm1160 (Pubitemid 40215840)
15. RR Rosato JA Almenara Y Dai S Grant 2003 Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells Mol Cancer Ther 2 12 1273 1284 1:CAS:528:DC%2BD2cXnvFSr 14707268
16. S Nakata T Yoshida M Horinaka T Shiraishi M Wakada T Sakai 2004 Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells Oncogene 23 37 6261 6271 10.1038/sj.onc.1207830 1:CAS:528:DC%2BD2cXmslCmt7g%3D 15208660 10.1038/sj.onc.1207830 (Pubitemid 39215296)
17. TE Fandy S Shankar DD Ross E Sausville RK Srivastava 2005 Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma Neoplasia 7 7 646 657 1:CAS:528:DC%2BD2MXps1CntL4%3D 16026644 10.1593/neo.04655 (Pubitemid 41099418)
18. A Nebbioso N Clarke E Voltz E Germain C Ambrosino P Bontempo R Alvarez EM Schiavone F Ferrara F Bresciani A Weisz AR de Lera H Gronemeyer L Altucci 2005 Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells Nat Med 11 1 77 84 1:CAS:528:DC%2BD2MXovF2l 15619633 10.1038/nm1161 (Pubitemid 40215841)
19. P Klener J Molinsky T Simonova E Necas L Andera J Zivny 2008 Acquired resistance to tumor necrosis factor-related apoptosis- inducing ligand (TRAIL): histone deacetylase inhibitors resensitize TRAIL-resistant Jurkat acute lymphocytic leukemia cells ASH Annu Meet Abstr 112 11 5032 EP -
20. M MacFarlane N Harper RT Snowden MJ Dyer GA Barnett JH Pringle GM Cohen 2002 Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia Oncogene 21 44 6809 6818 10.1038/sj.onc.1205853 1:CAS:528:DC%2BD38XntFentLY%3D 12360407 10.1038/sj.onc.1205853 (Pubitemid 35221923)
21. S Inoue N Harper R Walewska MJS Dyer GM Cohen 2009 Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis Mol Cancer Ther 8 11 3088 3097 10.1158/1535-7163.MCT-09- 0451 1:CAS:528:DC%2BD1MXhtlyrt7%2FJ 19887558 10.1158/1535-7163.MCT-09-0451
22. S Inoue M MacFarlane N Harper LMC Wheat MJS Dyer GM Cohen 2004 Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies Cell Death Differ 11 Suppl 2 S193 S206 10.1038/sj.cdd.4401535 1:CAS:528:DC%2BD2cXhtVyqtrnP 15608694 10.1038/sj.cdd.4401535
23. S Inoue D Twiddy MJS Dyer GM Cohen 2006 Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis Cell Death Differ 13 12 2160 2162 10.1038/sj.cdd.4401977 1:CAS:528:DC%2BD28XhtF2ns77M 16729023 10.1038/sj.cdd.4401977 (Pubitemid 44742701)
24. F Guo C Sigua J Tao P Bali P George Y Li S Wittmann L Moscinski P Atadja K Bhalla 2004 Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells Cancer Res 64 7 2580 2589 1:CAS:528:DC%2BD2cXis1yjurc%3D 15059915 10.1158/0008-5472.CAN-03-2629 (Pubitemid 38523916)
25. TE Wood S Dalili CD Simpson MA Sukhai R Hurren K Anyiwe X Mao F Suarez Saiz M Gronda Y Eberhard N MacLean T Ketela JC Reed J Moffat MD Minden RA Batey AD Schimmer 2010 Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands Mol Cancer Ther 9 1 246 256 10.1158/1535-7163.MCT-09-0495 1:CAS:528:DC%2BC3cXktVOhsQ%3D%3D 20053768 10.1158/1535-7163.MCT-09-0495
26. T Sanda T Okamoto Y Uchida H Nakagawa S Iida S Kayukawa T Suzuki T Oshizawa T Suzuki N Miyata R Ueda 2007 Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells Leuk Official Journal Leuk Soc Am Leuk Res Fund UK 21 11 2344 2353 10.1038/sj.leu.2404902 1:CAS:528:DC%2BD2sXht1WgsbnK (Pubitemid 350011707)
27. DM Lucas ME Davis MR Parthun AP Mone S Kitada KD Cunningham EL Flax J Wickham JC Reed JC Byrd MR Grever 2004 The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells Leuk Official Journal Leuk Soc Am Leuk Res Fund UK 18 7 1207 1214 10.1038/sj.leu.2403388 1:CAS:528:DC%2BD2cXkvF2ku7w%3D (Pubitemid 39023130)
28. DM Lucas L Alinari DA West ME Davis RB Edwards AJ Johnson KA Blum CC Hofmeister MA Freitas MR Parthun D Wang A Lehman X Zhang D Jarjoura SK Kulp CM Croce MR Grever C-S Chen RA Baiocchi JC Byrd 2010 The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo PLoS ONE 5 6 e10941 10.1371/journal.pone.0010941 20532179 10.1371/journal.pone.0010941 1:CAS:528:DC%2BC3cXntlaqt70%3D
29. R Tang A-M Faussat P Majdak J-Y Perrot D Chaoui O Legrand J-P Marie 2004 Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 Leuk Official Journal Leuk Soc Am Leuk Res Fund UK 18 7 1246 1251 10.1038/sj.leu.2403390 1:CAS:528:DC%2BD2cXkvF2ku7o%3D (Pubitemid 39023135)
30. JC Morales MJ Ruiz-Magaña D Carranza G Ortiz-Ferrón C Ruiz-Ruiz 2010 HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis Cancer Lett 10.1016/j.canlet.2010.04.029 20580868
31. AJ Frew RK Lindemann BP Martin CJP Clarke J Sharkey DA Anthony K-M Banks NM Haynes P Gangatirkar K Stanley JE Bolden K Takeda H Yagita JP Secrist MJ Smyth RW Johnstone 2008 Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist Proc Natl Acad Sci USA 105 32 11317 11322 10.1073/pnas.0801868105 1:CAS:528:DC%2BD1cXhtVShu7zF 18685088 10.1073/pnas.0801868105
32. RK Lindemann A Newbold KF Whitecross LA Cluse AJ Frew L Ellis S Williams AP Wiegmans AE Dear CL Scott M Pellegrini A Wei VM Richon PA Marks SW Lowe MJ Smyth RW Johnstone 2007 Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma Proc Natl Acad Sci USA 104 19 8071 8076 10.1073/pnas.0702294104 1:CAS:528: DC%2BD2sXmtFSnu7s%3D 17470784 10.1073/pnas.0702294104 (Pubitemid 47185877)
33. L Ellis M Bots RK Lindemann JE Bolden A Newbold LA Cluse CL Scott A Strasser P Atadja SW Lowe RW Johnstone 2009 The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy Blood 114 2 380 393 10.1182/blood-2008-10-182758 1:CAS:528:DC%2BD1MXovVKlsrg%3D 19383971 10.1182/blood-2008-10-182758
34. JE Chipuk T Moldoveanu F Llambi MJ Parsons DR Green 2010 The BCL-2 family reunion Mol Cell 37 3 299 310 10.1016/j.molcel.2010.01.025 1:CAS:528: DC%2BC3cXlt1Kktb4%3D 20159550 10.1016/j.molcel.2010.01.025
35. XD Zhang SK Gillespie JM Borrow P Hersey 2004 The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells Mol Cancer Ther 3 4 425 435 1:CAS:528:DC%2BD2cXivFyhu7o%3D 15078986
36. A Romanski B Bacic G Bug H Pfeifer H Gul S Remiszewski D Hoelzer P Atadja M Ruthardt OG Ottmann 2004 Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia Haematologica 89 4 419 426 1:CAS:528:DC%2BD2cXot1Orurw%3D 15075075
37. CS Mitsiades NS Mitsiades CJ McMullan V Poulaki R Shringarpure T Hideshima M Akiyama D Chauhan N Munshi X Gu C Bailey M Joseph TA Libermann VM Richon PA Marks KC Anderson 2004 Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci USA 101 2 540 545 10.1073/pnas.2536759100 1:CAS:528:DC%2BD2cXmsFGnsA%3D%3D 14695887 10.1073/pnas.2536759100 (Pubitemid 38084672)
38. MB Wozniak R Villuendas JR Bischoff CB Aparicio JF Martínez Leal P de La Cueva ME Rodriguez B Herreros D Martin-Perez MI Longo M Herrera MA Piris PL Ortiz-Romero 2010 Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma Haematologica 95 4 613 621 10.3324/haematol.2009.013870 1:CAS:528:DC%2BC3cXhtlWjsL7E 20133897 10.3324/haematol.2009.013870
39. SB Khan T Maududi K Barton J Ayers S Alkan 2004 Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma Br J Haematol 125 2 156 161 10.1111/j.1365-2141.2004.04882.x 1:CAS:528: DC%2BD2cXktlKrsL8%3D 15059137 10.1111/j.1365-2141.2004.04882.x (Pubitemid 38534966)
40. MJ Peart GK Smyth RK van Laar DD Bowtell VM Richon PA Marks AJ Holloway RW Johnstone 2005 Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci USA 102 10 3697 3702 10.1073/pnas.0500369102 1:CAS:528:DC%2BD2MXisVOgsb0%3D 15738394 10.1073/pnas.0500369102 (Pubitemid 40354674)
41. D Buglio GV Georgakis S Hanabuchi K Arima NM Khaskhely Y-J Liu A Younes 2008 Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood 112 4 1424 1433 10.1182/blood-2008-01-133769 1:CAS:528:DC%2BD1cXpvVOktb0%3D 18541724 10.1182/blood-2008-01-133769
42. VR Fantin A Loboda CP Paweletz RC Hendrickson JW Pierce JA Roth L Li F Gooden S Korenchuk XS Hou EA Harrington S Randolph JF Reilly CM Ware ME Kadin SR Frankel VM Richon 2008 Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma Cancer Res 68 10 3785 3794 10.1158/0008-5472.CAN-07-6091 1:CAS:528:DC%2BD1cXlvVOitbY%3D 18483262 10.1158/0008-5472.CAN-07-6091
43. Y Zhang M Adachi R Kawamura K Imai 2006 Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis Cell Death Differ 13 1 129 140 10.1038/sj.cdd.4401686 1:CAS:528:DC%2BD2MXht1yktbrN 15947789 10.1038/sj.cdd.4401686
44. Y Wei T Kadia W Tong M Zhang Y Jia H Yang Y Hu FP Tambaro J Viallet S O'brien G Garcia-Manero 2010 The combination of a histone deacecetylase inhibitor with the BH3-Mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy Clin Cancer Res 10.1158/1078-0432.CCR- 10-0032
45. P Maiso X Carvajal-Vergara EM Ocio R López-Pérez G Mateo N Gutiérrez P Atadja A Pandiella JF San Miguel 2006 The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance Cancer Res 66 11 5781 5789 10.1158/0008-5472.CAN-05-4186 1:CAS:528: DC%2BD28XltFyjtb8%3D 16740717 10.1158/0008-5472.CAN-05-4186 (Pubitemid 43927132)
46. J Chen W Fiskus K Eaton P Fernandez Y Wang R Rao P Lee R Joshi Y Yang R Kolhe R Balusu P Chappa K Natarajan A Jillella P Atadja KN Bhalla 2009 Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77-based mechanism Blood 113 17 4038 4048 10.1182/blood-2008-08-176024 1:CAS:528:DC%2BD1MXlsVWrsbY%3D 19074726 10.1182/blood-2008-08-176024
47. LM High B Szymanska U Wilczynska-Kalak N Barber R O'Brien SL Khaw IB Vikstrom AW Roberts RB Lock 2009 The BH3-mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs Mol Pharmacol 10.1124/mol.109.060780 20038611
48. MJ Peart KM Tainton AA Ruefli AE Dear KA Sedelies LA O'Reilly NJ Waterhouse JA Trapani RW Johnstone 2003 Novel mechanisms of apoptosis induced by histone deacetylase inhibitors Cancer Res 63 15 4460 4471 1:CAS:528: DC%2BD3sXmtFersrs%3D 12907619
49. W Shao JD Growney Y Feng G O'Connor M Pu W Zhu Y-M Yao P Kwon S Fawell P Atadja 2010 Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: defining molecular mechanisms of resistance Int J Cancer J Int Cancer 10.1002/ijc.25218
50. L Ellis Y Pan GK Smyth DJ George C McCormack R Williams-Truax M Mita J Beck H Burris G Ryan P Atadja D Butterfoss M Dugan K Culver RW Johnstone HM Prince 2008 Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma Clin Cancer Res 14 14 4500 4510 10.1158/1078-0432.ccr-07-4262 1:CAS:528:DC%2BD1cXosFGitL0%3D 18628465 10.1158/1078-0432.CCR-07-4262
51. JS Ungerstedt Y Sowa WS Xu Y Shao M Dokmanovic G Perez L Ngo A Holmgren X Jiang PA Marks 2005 Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors Proc Natl Acad Sci USA 102 3 673 678 10.1073/pnas.0408732102 1:CAS:528:DC%2BD2MXis1Cqs78%3D 15637150 10.1073/pnas.0408732102 (Pubitemid 40282724)
52. RR Rosato JA Almenara S Grant 2003 The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1 Cancer Res 63 13 3637 3645 1:CAS:528:DC%2BD3sXltVGrurc%3D 12839953
53. RR Rosato SC Maggio JA Almenara SG Payne P Atadja S Spiegel P Dent S Grant 2006 The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide Mol Pharmacol 69 1 216 225 10.1124/mol.105.017145 1:CAS:528:DC%2BD28XktlWntw%3D%3D 16189296 (Pubitemid 43048908)
54. RR Rosato SS Kolla SK Hock JA Almenara A Patel S Amin P Atadja PB Fisher P Dent S Grant 2010 Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway J Biol Chem 285 13 10064 10077 10.1074/jbc.M109.095208 1:CAS:528:DC%2BC3cXjsFehsrY%3D 20065354 10.1074/jbc.M109.095208
55. AA Ruefli MJ Ausserlechner D Bernhard VR Sutton KM Tainton R Kofler MJ Smyth RW Johnstone 2001 The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of bid and production of reactive oxygen species Proc Natl Acad Sci USA 98 19 10833 10838 10.1073/pnas.191208598 1:CAS:528: DC%2BD3MXntVGmsLY%3D 11535817 10.1073/pnas.191208598 (Pubitemid 32878706)
56. Y Hu W Lu G Chen H Zhang Y Jia Y Wei H Yang W Zhang W Fiskus K Bhalla M Keating P Huang G Garcia-Manero 2010 Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate Blood 10.1182/blood-2009-11-256354
57. LM Butler X Zhou WS Xu HI Scher RA Rifkind PA Marks VM Richon 2002 The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin Proc Natl Acad Sci USA 99 18 11700 11705 10.1073/pnas.182372299 1:CAS:528:DC%2BD38XntFWqsbY%3D 12189205 10.1073/pnas.182372299 (Pubitemid 34994462)
58. A Rodriguez-Gonzalez T Lin AK Ikeda T Simms-Waldrip C Fu KM Sakamoto 2008 Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation Cancer Res 68 8 2557 2560 10.1158/0008-5472.CAN- 07-5989 1:CAS:528:DC%2BD1cXks1Git7o%3D 18413721 10.1158/0008-5472.CAN-07-5989 (Pubitemid 351556250)
59. EL Davenport GJ Morgan FE Davies 2008 Untangling the unfolded protein response Cell Cycle 7 7 865 869 1:CAS:528:DC%2BD1cXnslWqs7s%3D 18414035 10.4161/cc.7.7.5615
60. D Ron P Walter 2007 Signal integration in the endoplasmic reticulum unfolded protein response Nat Rev Mol Cell Biol 8 7 519 529 10.1038/nrm2199 1:CAS:528:DC%2BD2sXmvVaktLY%3D 17565364 10.1038/nrm2199 (Pubitemid 46985379)
61. EL Davenport HE Moore AS Dunlop SY Sharp P Workman GJ Morgan FE Davies 2007 Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells Blood 110 7 2641 2649 1:CAS:528:DC%2BD2sXhtFCnsbnM 17525289 10.1182/blood-2006-11-053728 (Pubitemid 47523188)
62. RR Kopito 2003 The missing linker: an unexpected role for a histone deacetylase Mol Cell 12 6 1349 1351 1:CAS:528:DC%2BD2cXhsVOmtw%3D%3D 14690590 10.1016/S1097-2765(03)00498-2 (Pubitemid 38037005)
63. Y Kawaguchi JJ Kovacs A McLaurin JM Vance A Ito TP Yao 2003 The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress Cell 115 6 727 738 1:CAS:528:DC%2BD3sXhtVWgurfL 14675537 10.1016/S0092-8674(03)00939-5 (Pubitemid 38030301)
64. Zhao Z, Xu H, Gong W (2009) Histone Deacetylase 6 (HDAC6) is an Independent Deacetylase for alpha-Tubulin. Protein Pept Lett
65. T Hideshima JE Bradner J Wong D Chauhan P Richardson SL Schreiber KC Anderson 2005 Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma Proc Natl Acad Sci USA 102 24 8567 8572 1:CAS:528:DC%2BD2MXlsFCgtro%3D 15937109 10.1073/pnas.0503221102 (Pubitemid 40862776)
66. Y Wang S-Y Wang X-H Zhang M Zhao C-M Hou Y-J Xu Z-Y Du X-D Yu 2007 FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70 Biochem Biophys Res Commun 356 4 998 1003 10.1016/j.bbrc.2007.03.076 1:CAS:528:DC%2BD2sXjvFOmtLw%3D 17397803 10.1016/j.bbrc.2007.03.076 (Pubitemid 46529390)
67. P Bali M Pranpat J Bradner M Balasis W Fiskus F Guo K Rocha S Kumaraswamy S Boyapalle P Atadja E Seto K Bhalla 2005 Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 29 26729 26734 10.1074/jbc.C500186200 1:CAS:528:DC%2BD2MXmt1Ggs7w%3D 15937340 10.1074/jbc.C500186200 (Pubitemid 41040705)
68. R Rao S Nalluri W Fiskus A Savoie KM Buckley K Ha R Balusu A Joshi V Coothankandaswamy J Tao E Sotomayor PW Atadja KN Bhalla 2010 Role of C/EBP homologous protein (CHOP) in panobinostat-mediated potentiation of bortezomib-induced lethal ER stress in mantle cell lymphoma cells Clin Cancer Res 10.1158/1078-0432.CCR-10-0529
69. RH Prabhala D Pelluru M Fulciniti HK Prabhala P Nanjappa W Song C Pai S Amin Y-T Tai PG Richardson IM Ghobrial SP Treon JF Daley KC Anderson JL Kutok NC Munshi 2010 Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma Blood 115 26 5385 5392 10.1182/blood-2009-10-246660 1:CAS:528:DC%2BC3cXpt1yntrk%3D 20395418 10.1182/blood-2009-10-246660
70. R Rao W Fiskus Y Yang P Lee R Joshi P Fernandez A Mandawat P Atadja JE Bradner K Bhalla 2008 HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 112 5 1886 1893 10.1182/blood-2008-03-143644 1:CAS:528:DC%2BD1cXhtVylu7jI 18591380 10.1182/blood-2008-03-143644
71. L Catley E Weisberg T Kiziltepe YT Tai T Hideshima P Neri P Tassone P Atadja D Chauhan NC Munshi KC Anderson 2006 Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells Blood 108 10 3441 3449 1:CAS:528:DC%2BD28Xht1ahsLzM 16728695 10.1182/blood-2006-04-016055
72. S Fotheringham MT Epping L Stimson O Khan V Wood F Pezzella R Bernards NB La Thangue 2009 Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis Cancer Cell 15 1 57 66 10.1016/j.ccr.2008.12.001 1:CAS:528:DC%2BD1MXptVKjsg%3D%3D 19111881 10.1016/j.ccr.2008.12.001
73. O Khan S Fotheringham V Wood L Stimson C Zhang F Pezzella M Duvic DJ Kerr NB La Thangue 2010 HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy Proc Natl Acad Sci USA 107 14 6532 6537 10.1073/pnas.0913912107 1:CAS:528:DC%2BC3cXkslymsrs%3D 20308564 10.1073/pnas.0913912107
74. C Boyault Y Zhang S Fritah C Caron B Gilquin SH Kwon C Garrido T-P Yao C Vourc'h P Matthias S Khochbin 2007 HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates Genes Dev 21 17 2172 2181 10.1101/gad.436407 1:CAS:528:DC%2BD2sXhtVaks73M 17785525 10.1101/gad.436407 (Pubitemid 47360839)
75. EM Ocio D Vilanova P Atadja P Maiso E Crusoe D Fernández- Lázaro M Garayoa L San-Segundo T Hernández-Iglesias E de Álava W Shao Y-M Yao A Pandiella JF San-Miguel 2009 In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma Haematologica 10.3324/haematol.2009.015495 19951978
76. Buglio D, Mamidipudi V, Khaskhely NM, Brady H, Heise C, Besterman J, Martell RE, MacBeth K, Younes A (2010) The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol Epub
77. S Harrison H Quach K Yuen A Strayer M Copeman S Peinert M Bishton M Wolf H Januszewicz M Kenealy K Herbert D Westerman D Carney J Seymour R Johnstone D Ritchie M Prince 2008 High response rates with the combination of bortezomib, dexamethasone and the pan-histone deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma in a phase I/II clinical trial ASH Annu Meet Abstr 112 11 3698 EP -
78. RL Piekarz R Frye M Turner JJ Wright SL Allen MH Kirschbaum J Zain HM Prince JP Leonard LJ Geskin C Reeder D Joske WD Figg ER Gardner SM Steinberg ES Jaffe M Stetler-Stevenson S Lade AT Fojo SE Bates 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 32 5410 5417 10.1200/jco.2008.21.6150 1:CAS:528:DC%2BD1MXhsFKkt7vO 19826128 10.1200/JCO.2008.21.6150
79. SL Harris AJ Levine 2005 The p53 pathway: positive and negative feedback loops Oncogene 24 17 2899 2908 10.1038/sj.onc.1208615 1:CAS:528: DC%2BD2MXjtlehs7c%3D 15838523 10.1038/sj.onc.1208615 (Pubitemid 40638098)
80. W Gu RG Roeder 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain Cell 90 4 595 606 1:CAS:528: DyaK2sXlvFKmtLc%3D 9288740 10.1016/S0092-8674(00)80521-8 (Pubitemid 27357952)
81. J Luo F Su D Chen A Shiloh W Gu 2000 Deacetylation of p53 modulates its effect on cell growth and apoptosis Nature 408 6810 377 381 10.1038/35042612 1:CAS:528:DC%2BD3cXosVertbg%3D 11099047 10.1038/35042612
82. T Terui K Murakami R Takimoto M Takahashi K Takada T Murakami S Minami T Matsunaga T Takayama J Kato Y Niitsu 2003 Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors Cancer Res 63 24 8948 8954 1:CAS:528:DC%2BD3sXhtVSqtbnM 14695212
83. K Sakaguchi JE Herrera S Saito T Miki M Bustin A Vassilev CW Anderson E Appella 1998 DNA damage activates p53 through a phosphorylation-acetylation cascade Genes Dev 12 18 2831 2841 1:CAS:528:DyaK1cXmtFCkurk%3D 9744860 10.1101/gad.12.18.2831
84. Y Tang W Zhao Y Chen Y Zhao W Gu 2008 Acetylation is indispensable for p53 activation Cell 133 4 612 626 10.1016/j.cell.2008.03.025 1:CAS:528:DC%2BD1cXmsVOrurs%3D 18485870 10.1016/j.cell.2008.03.025 (Pubitemid 351636297)
85. LJ Juan WJ Shia MH Chen WM Yang E Seto YS Lin CW Wu 2000 Histone deacetylases specifically down-regulate p53-dependent gene activation J Biol Chem 275 27 20436 20443 1:CAS:528:DC%2BD3cXkvVyhsrs%3D 10777477 10.1074/jbc.M000202200 (Pubitemid 30457621)
86. S Spange T Wagner T Heinzel OH Krämer 2009 Acetylation of non-histone proteins modulates cellular signalling at multiple levels Int J Biochem Cell Biol 41 1 185 198 10.1016/j.biocel.2008.08.027 1:CAS:528: DC%2BD1cXhsVWnu7zP 18804549 10.1016/j.biocel.2008.08.027
87. CD Palani JF Beck J Sonnemann 2010 Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression Investig New Drugs 10.1007/s10637-010-9510-7
88. KL Harms X Chen 2007 Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity Cancer Res 67 7 3145 3152 10.1158/0008-5472.CAN-06-4397 1:CAS:528:DC%2BD2sXksVGlu7w%3D 17409421 10.1158/0008-5472.CAN-06-4397 (Pubitemid 46724851)
89. Y Zhao S Lu L Wu G Chai H Wang Y Chen J Sun Y Yu W Zhou Q Zheng M Wu GA Otterson W-G Zhu 2006 Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1) Mol Cell Biol 26 7 2782 2790 10.1128/MCB.26.7.2782-2790.2006 1:CAS:528: DC%2BD28XivFSrt7w%3D 16537920 10.1128/MCB.26.7.2782-2790.2006
90. F Condorelli I Gnemmi A Vallario AA Genazzani PL Canonico 2008 Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells Br J Pharmacol 153 4 657 668 10.1038/sj.bjp.0707608 1:CAS:528:DC%2BD1cXitVKjsr8%3D 18059320 10.1038/sj.bjp.0707608 (Pubitemid 351271755)
91. Y Sowa T Orita S Minamikawa-Hiranabe T Mizuno H Nomura T Sakai 1999 Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor Cancer Res 59 17 4266 4270 1:CAS:528:DyaK1MXlvVSmsrc%3D 10485470 (Pubitemid 29418741)
92. A Saito T Yamashita Y Mariko Y Nosaka K Tsuchiya T Ando T Suzuki T Tsuruo O Nakanishi 1999 A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors Proc Natl Acad Sci USA 96 8 4592 4597 1:CAS:528:DyaK1MXjs1ylsbk%3D 10200307 10.1073/pnas.96.8.4592 (Pubitemid 29190381)
93. C-Y Gui L Ngo WS Xu VM Richon PA Marks 2004 Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 Proc Natl Acad Sci USA 101 5 1241 1246 10.1073/pnas.0307708100 1:CAS:528:DC%2BD2cXhtlWjt7k%3D 14734806 10.1073/pnas.0307708100 (Pubitemid 38182673)
94. RW Johnstone JD Licht 2003 Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4 1 13 18 1:CAS:528:DC%2BD3sXmt1SltL0%3D 12892709 10.1016/S1535-6108(03)00165-X (Pubitemid 36904157)
95. PA Marks VM Richon RA Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 15 1210 1216 1:CAS:528:DC%2BD3cXlvFyhsb8%3D 10922406 10.1093/jnci/92.15.1210
96. V Sandor A Senderowicz S Mertins D Sackett E Sausville MV Blagosklonny SE Bates 2000 P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228 Br J Cancer 83 6 817 825 10.1054/bjoc.2000.1327 1:CAS:528:DC%2BD3cXntFOhsLo%3D 10952788 10.1054/bjoc.2000.1327
97. N Kawamata J Chen HP Koeffler 2007 Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 7 2667 2673 10.1182/blood-2005-11-026344 1:CAS:528:DC%2BD2sXhtFCnsbnP 17606765 10.1182/blood-2005-11-026344 (Pubitemid 47523191)
98. A Burgess A Ruefli H Beamish R Warrener N Saunders R Johnstone B Gabrielli 2004 Histone deacetylase inhibitors specifically kill nonproliferating tumour cells Oncogene 23 40 6693 6701 10.1038/sj.onc.1207893 1:CAS:528:DC%2BD2cXntFGnu7o%3D 15235588 10.1038/sj.onc.1207893 (Pubitemid 39280001)
99. AJ Burgess S Pavey R Warrener LJ Hunter TJ Piva EA Musgrove N Saunders PG Parsons BG Gabrielli 2001 Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity Mol Pharmacol 60 4 828 837 1:CAS:528:DC%2BD3MXnt1ersrk%3D 11562446
100. TJ Mitchell S John 2005 Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas Immunology 114 3 301 312 10.1111/j.1365-2567.2005.02091.x 1:CAS:528:DC%2BD2MXit1Wgsr0%3D 15720432 10.1111/j.1365-2567.2005.02091.x (Pubitemid 40314803)
101. M Paulson S Pisharody L Pan S Guadagno AL Mui DE Levy 1999 Stat protein transactivation domains recruit p300/CBP through widely divergent sequences J Biol Chem 274 36 25343 25349 1:CAS:528:DyaK1MXmtVWitbo%3D 10464260 10.1074/jbc.274.36.25343 (Pubitemid 29418553)
102. I Nusinzon CM Horvath 2003 Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1 Proc Natl Acad Sci USA 100 25 14742 14747 10.1073/pnas.2433987100 1:CAS:528:DC%2BD3sXpvFaqs7Y%3D 14645718 10.1073/pnas.2433987100 (Pubitemid 37517961)
103. I Nusinzon CM Horvath 2005 Unexpected roles for deacetylation in interferon- and cytokine-induced transcription J Interferon Cytokine Res 25 12 745 748 10.1089/jir.2005.25.745 1:CAS:528:DC%2BD2MXhtlCnsrnO 16375602 10.1089/jir.2005.25.745 (Pubitemid 43068485)
104. A Rascle JA Johnston B Amati 2003 Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5 Mol Cell Biol 23 12 4162 4173 1:CAS:528:DC%2BD3sXks1ykurs%3D 12773560 10.1128/MCB.23.12.4162-4173.2003 (Pubitemid 36666421)
105. L Klampfer J Huang L-A Swaby L Augenlicht 2004 Requirement of histone deacetylase activity for signaling by STAT1 J Biol Chem 279 29 30358 30368 10.1074/jbc.M401359200 1:CAS:528:DC%2BD2cXlsFKiurg%3D 15123634 10.1074/jbc.M401359200 (Pubitemid 38937963)
106. H Yu D Pardoll R Jove 2009 STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 11 798 10.1038/nrc2734 1:CAS:528:DC%2BD1MXhtlSjur%2FP 19851315 10.1038/nrc2734
107. M Chatterjee T Stühmer P Herrmann K Bommert B Dörken RC Bargou 2004 Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells Blood 104 12 3712 3721 10.1182/blood-2004-04-1670 1:CAS:528:DC%2BD2cXhtVGltbzL 15297310 10.1182/blood-2004-04-1670 (Pubitemid 39564449)
108. M Chatterjee S Jain T Stühmer M Andrulis U Ungethüm R-J Kuban H Lorentz K Bommert M Topp D Krämer HK Müller-Hermelink H Einsele A Greiner RC Bargou 2007 STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival Blood 109 2 720 728 10.1182/blood-2006-05- 024372 1:CAS:528:DC%2BD2sXivVyrs7c%3D 17003370 10.1182/blood-2006-05-024372 (Pubitemid 46105974)
109. D Löffler K Brocke-Heidrich G Pfeifer C Stocsits J Hackermüller AK Kretzschmar R Burger M Gramatzki C Blumert K Bauer H Cvijic AK Ullmann PF Stadler F Horn 2007 Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer Blood 110 4 1330 1333 10.1182/blood-2007-03-081133 17496199 10.1182/blood-2007-03-081133 1:CAS:528:DC%2BD2sXptFKls7k%3D (Pubitemid 47281433)
110. S Alas B Bonavida 2003 Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin Cancer Res 9 1 316 326 1:CAS:528:DC%2BD3sXnt1Ortw%3D%3D 12538484
111. JF García FI Camacho M Morente M Fraga C Montalbán T Alvaro C Bellas A Castaño A Díez T Flores C Martin MA Martinez F Mazorra J Menárguez MJ Mestre M Mollejo AI Sáez L Sánchez MA Piris SHLS Group 2003 Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays Blood 101 2 681 689 10.1182/blood-2002-04-1128 12393683 10.1182/blood-2002-04-1128 1:CAS:528:DC%2BD3sXkvVajsg%3D%3D (Pubitemid 36077593)
112. B Lamprecht S Kreher I Anagnostopoulos K Jöhrens G Monteleone F Jundt H Stein M Janz B Dörken S Mathas 2008 Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha Blood 112 8 3339 3347 10.1182/blood-2008-01-134783 1:CAS:528:DC%2BD1cXht1Omur3N 18684866 10.1182/blood-2008-01-134783
113. D Baus E Pfitzner 2006 Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells Int J Cancer 118 6 1404 1413 10.1002/ijc.21539 1:CAS:528:DC%2BD28XhslCqsrk%3D 16206268 10.1002/ijc.21539
114. N Tsuyama I Danjoh K-I Otsuyama M Obata H Tahara T Ohta H Ishikawa 2005 IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3 Biochem Biophys Res Commun 337 1 201 208 10.1016/j.bbrc.2005.09.036 1:CAS:528:DC%2BD2MXhtVKis7%2FM 16188230 10.1016/j.bbrc.2005.09.036 (Pubitemid 41393780)
115. D Daigle C Megyola A El-Guindy L Gradoville D Tuck G Miller S Bhaduri-McIntosh 2010 Upregulation of STAT3 marks Burkitt lymphoma cells refractory to Epstein-Barr virus lytic cycle induction by HDAC inhibitors J Virol 84 2 993 1004 10.1128/JVI.01745-09 1:CAS:528:DC%2BC3cXisFyksr0%3D 19889776 10.1128/JVI.01745-09
116. LT Lam G Wright RE Davis G Lenz P Farinha L Dang JW Chan A Rosenwald RD Gascoyne LM Staudt 2008 Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood 111 7 3701 3713 10.1182/blood-2007-09- 111948 1:CAS:528:DC%2BD1cXktlWmtrw%3D 18160665 10.1182/blood-2007-09-111948
117. KW Eriksen K Kaltoft G Mikkelsen M Nielsen Q Zhang C Geisler MH Nissen C Röpke MA Wasik N Odum 2001 Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells Leukemia 15 5 787 793 1:CAS:528:DC%2BD3MXks1Kks7Y%3D 11368440 10.1038/sj.leu.2402093 (Pubitemid 32492702)
118. M Duvic R Talpur X Ni C Zhang P Hazarika C Kelly JH Chiao JF Reilly JL Ricker VM Richon SR Frankel 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 1 31 39 1:CAS:528:DC%2BD2sXivVyrt7g%3D 16960145 10.1182/blood-2006-06-025999 (Pubitemid 46053039)
119. FA Scheeren SA Diehl LA Smit T Beaumont M Naspetti RJ Bende B Blom K Karube K Ohshima CJM Van Noesel H Spits 2008 IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis Blood 111 9 4706 4715 10.1182/blood-2007-08-105643 1:CAS:528:DC%2BD1cXlsVSrsL4%3D 18296629 10.1182/blood-2007-08-105643
120. M Hinz P Lemke I Anagnostopoulos C Hacker D Krappmann S Mathas B Dörken M Zenke H Stein C Scheidereit 2002 Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity J Exp Med 196 5 605 617 1:CAS:528:DC%2BD38XmvFKqtLs%3D 12208876 10.1084/jem.20020062 (Pubitemid 35024439)
121. D Buglio G Georgiakis S Hanabuchi K Arima N Khaskhely Y Liu A Younes 2008 Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines Blood 10.1182/blood-2008-01-133769 18541724
122. G Wirnsberger D Hebenstreit G Posselt J Horejs-Hoeck A Duschl 2006 IL-4 induces expression of TARC/CCL17 via two STAT6 binding sites Eur J Immunol 36 7 1882 1891 10.1002/eji.200635972 1:CAS:528:DC%2BD28XnslOmsrc%3D 16810739 10.1002/eji.200635972 (Pubitemid 44089054)
123. D Hebenstreit G Wirnsberger J Horejs-Hoeck A Duschl 2006 Signaling mechanisms, interaction partners, and target genes of STAT6 Cytokine Growth Factor Rev 17 3 173 188 10.1016/j.cytogfr.2006.01.004 1:CAS:528: DC%2BD28Xltlelt74%3D 16540365 10.1016/j.cytogfr.2006.01.004 (Pubitemid 43816893)
124. BF Skinnider AJ Elia RD Gascoyne B Patterson L Trumper U Kapp TW Mak 2002 Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood 99 2 618 626 1:CAS:528:DC%2BD38XmslGrsg%3D%3D 11781246 10.1182/blood.V99.2.618 (Pubitemid 34533100)
125. H Yu R Jove 2004 The STATs of cancer-new molecular targets come of age Nat Rev Cancer 4 2 97 105 1:CAS:528:DC%2BD2cXhtlaqtb0%3D 14964307 10.1038/nrc1275
126. OH Krämer SK Knauer G Greiner E Jandt S Reichardt K-H Gührs RH Stauber FD Böhmer T Heinzel 2009 A phosphorylation-acetylation switch regulates STAT1 signaling Genes Dev 23 2 223 235 10.1101/gad.479209 19171783 10.1101/gad.479209 1:CAS:528:DC%2BD1MXhs1Krs7o%3D
127. OH Krämer D Baus SK Knauer S Stein E Jäger RH Stauber M Grez E Pfitzner T Heinzel 2006 Acetylation of Stat1 modulates NF-kappaB activity Genes Dev 20 4 473 485 10.1101/gad.364306 16481475 10.1101/gad.364306 1:CAS:528:DC%2BD28Xhslaqu7o%3D (Pubitemid 43244401)
128. Z-L Yuan Y-J Guan D Chatterjee YE Chin 2005 Stat3 dimerization regulated by reversible acetylation of a single lysine residue Science 307 5707 269 273 10.1126/science.1105166 1:CAS:528:DC%2BD2MXisVKktA%3D%3D 15653507 10.1126/science.1105166 (Pubitemid 40116244)
129. Y Dai S Chen LB Kramer VL Funk P Dent S Grant 2008 Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells Clin Cancer Res 14 2 549 558 10.1158/1078-0432.CCR-07-1934 1:CAS:528: DC%2BD1cXhtVKhsLc%3D 18223231 10.1158/1078-0432.CCR-07-1934 (Pubitemid 351226125)
130. C Zhang V Richon X Ni R Talpur M Duvic 2005 Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action J Investig Dermatol 125 5 1045 1052 1:CAS:528:DC%2BD2MXht1GrtrvN 16297208 10.1111/j.0022-202X.2005.23925.x
131. L-F Chen WC Greene 2004 Shaping the nuclear action of NF-kappaB Nat Rev Mol Cell Biol 5 5 392 401 10.1038/nrm1368 1:CAS:528:DC%2BD2cXjsFSltL0%3D 15122352 10.1038/nrm1368 (Pubitemid 38579476)
132. M Muratani WP Tansey 2003 How the ubiquitin-proteasome system controls transcription Nat Rev Mol Cell Biol 4 3 192 201 10.1038/nrm1049 1:CAS:528:DC%2BD3sXhsFajsLw%3D 12612638 10.1038/nrm1049 (Pubitemid 36288041)
133. T Hideshima H Ikeda D Chauhan Y Okawa N Raje K Podar C Mitsiades NC Munshi PG Richardson RD Carrasco KC Anderson 2009 Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells Blood 114 5 1046 1052 10.1182/blood-2009-01-199604 1:CAS:528:DC%2BD1MXps1eitLs%3D 19436050 10.1182/blood-2009-01-199604
134. C Li S Chen P Yue X Deng S Lonial FR Khuri S-Y Sun 2010 The proteasome inhibitor PS-341 (Bortezomib) induces calpain-dependent I{kappa}B{alpha} degradation J Biol Chem 10.1074/jbc.M109.072694
135. L-F Chen WC Greene 2003 Regulation of distinct biological activities of the NF-kappaB transcription factor complex by acetylation J Mol Med 81 9 549 557 10.1007/s00109-003-0469-0 1:CAS:528:DC%2BD3sXnt1Kit7s%3D 12920522 10.1007/s00109-003-0469-0 (Pubitemid 37214993)
136. T Maeda M Towatari H Kosugi H Saito 2000 Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells Blood 96 12 3847 3856 1:CAS:528:DC%2BD3cXosVGntbk%3D 11090069
137. WJ Magner AL Kazim C Stewart MA Romano G Catalano C Grande N Keiser F Santaniello TB Tomasi 2000 Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors J Immunol 165 12 7017 7024 1:CAS:528:DC%2BD3cXovFygsrs%3D 11120829
138. ANH Khan CJ Gregorie TB Tomasi 2008 Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells Cancer Immunol Immunother 57 5 647 654 10.1007/s00262-007-0402-4 1:CAS:528:DC%2BD1cXitlKjsbs%3D 18046553 10.1007/s00262-007-0402-4
139. ANH Khan WJ Magner TB Tomasi 2007 An epigenetic vaccine model active in the prevention and treatment of melanoma J Transl Med 5 64 10.1186/1479-5876-5- 64 18070359 10.1186/1479-5876-5-64 1:CAS:528:DC%2BD1cXltlarsbs%3D (Pubitemid 351234171)
140. M Gialitakis A Kretsovali C Spilianakis L Kravariti J Mages R Hoffmann AK Hatzopoulos J Papamatheakis 2006 Coordinated changes of histone modifications and HDAC mobilization regulate the induction of MHC class II genes by Trichostatin A Nucleic Acids Res 34 3 765 772 10.1093/nar/gkj462 1:CAS:528:DC%2BD28Xhs1SktLY%3D 16452299 10.1093/nar/gkj462 (Pubitemid 43380662)
141. M Campoli S Ferrone 2008 HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance Oncogene 27 45 5869 5885 10.1038/onc.2008.273 1:CAS:528:DC%2BD1cXhtF2msbnF 18836468 10.1038/onc.2008.273
142. ANH Khan TB Tomasi 2008 Histone deacetylase regulation of immune gene expression in tumor cells Immunol Res 40 2 164 178 10.1007/s12026-007-0085-0 1:CAS:528:DC%2BD1cXivFygsLc%3D 18213528 10.1007/s12026-007-0085-0 (Pubitemid 351912834)
143. H Chambost N Van Baren F Brasseur D Godelaine L Xerri SJ Landi I Theate J Plumas GC Spagnoli G Michel PG Coulie D Olive 2000 Expression of gene MAGE-A4 in Reed-Sternberg cells Blood 95 11 3530 3533 1:CAS:528:DC%2BD3cXjsl2isb0%3D 10828039
144. C Cruz A Leen U Gerdemann A Christin T Tripic J Shafer A Younes T Horton E Shpall H Heslop C Rooney C Bollard 2009 Immune-based therapies targeting mage-A4 for relapsed/refractory Hodgkin's lymphoma after stem cell transplant ASH Annu Meet Abstr 114 22 4089 EP -
145. F Wischnewski K Pantel H Schwarzenbach 2006 Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells Mol Cancer Res 4 5 339 349 10.1158/1541-7786.MCR-05-0229 1:CAS:528:DC%2BD28Xktlymsb8%3D 16687489 10.1158/1541-7786.MCR-05-0229 (Pubitemid 43837335)
146. S Shichijo A Yamada K Sagawa O Iwamoto M Sakata K Nagai K Itoh 1996 Induction of MAGE genes in lymphoid cells by the demethylating agent 5-aza-2′-deoxycytidine Jpn J Cancer Res 87 7 751 756 1:CAS:528: DyaK28Xks1ejtL8%3D 8698626
147. O Goodyear A Agathanggelou I Novitzky-Basso S Siddique T McSkeane G Ryan P Vyas J Cavenagh T Stankovic P Moss C Craddock 2010 Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 10.1182/blood-2009-11-249474 20530795
148. A Moreno S Szmania J Shi B Barlogie G Prentice F van Rhee 2008 Induction of the cancer-testis antigen MAGE-A3 in myeloma cell lines by 5′azacitidine and MGCD0103 ASCO Meet Abstr 26 15-suppl 14008 EP -
149. NM Khaskhely D Buglio J Shafer CM Bollard A Younes 2009 The histone deacetylase (HDAC) inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechanism of immune modulation and apoptosis induction Blood ASH Annu Meet Abstr 114 22 1562-
150. A Moreno-Bost S Szmania K Stone J Shi T Garg J Shaughnessy B Barlogie H Prentice F van Rhee 2008 Recognition of myeloma by MAGE-A3 specific cytotoxic T lymphocytes induced by treatment with azacitidine and MGCD0103 ASH Annu Meet Abstr 112 11 3674 EP -
151. T Stankovic A McLarnon A Agathanggelou O Goodyear C Craddock P Moss 2008 Epigenetic manipulation of cancer testis antigen (CTA) expression: a strategy for manipulating the graft-versus leukaemia response in patients allografted for haematological malignancies ASH Annu Meet Abstr 112 11 600 EP -
152. DH Raulet N Guerra 2009 Oncogenic stress sensed by the immune system: role of natural killer cell receptors Nat Rev Immunol 9 8 568 580 10.1038/nri2604 1:CAS:528:DC%2BD1MXovFylsLY%3D 19629084 10.1038/nri2604
153. S Gasser DH Raulet 2006 Activation and self-tolerance of natural killer cells Immunol Rev 214 130 142 10.1111/j.1600-065X.2006.00460.x 1:CAS:528:DC%2BD28XhtlClsr%2FO 17100881 10.1111/j.1600-065X.2006.00460.x (Pubitemid 44707907)
154. S Armeanu M Bitzer UM Lauer S Venturelli A Pathil M Krusch S Kaiser J Jobst I Smirnow A Wagner A Steinle HR Salih 2005 Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate Cancer Res 65 14 6321 6329 10.1158/0008-5472.CAN-04-4252 1:CAS:528:DC%2BD2MXmt1egsbg%3D 16024634 10.1158/0008-5472.CAN-04-4252 (Pubitemid 40994418)
155. S Skov MT Pedersen L Andresen PT Straten A Woetmann N Odum 2005 Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B Cancer Res 65 23 11136 11145 10.1158/0008-5472.CAN-05-0599 1:CAS:528:DC%2BD2MXht1KjsrrK 16322264 10.1158/0008-5472.CAN-05-0599 (Pubitemid 41713385)
156. A Rohner U Langenkamp U Siegler CP Kalberer A Wodnar-Filipowicz 2007 Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis Leuk Res 31 10 1393 1402 10.1016/j.leukres.2007.02.020 1:CAS:528:DC%2BD2sXovFKntb8%3D 17391757 10.1016/j.leukres.2007.02.020 (Pubitemid 47212430)
157. S Diermayr H Himmelreich B Durovic A Mathys-Schneeberger U Siegler U Langenkamp J Hofsteenge A Gratwohl A Tichelli M Paluszewska W Wiktor-Jedrzejczak CP Kalberer A Wodnar-Filipowicz 2008 NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood 111 3 1428 1436 10.1182/blood-2007-07-101311 1:CAS:528:DC%2BD1cXhvFejtbY%3D 17993609 10.1182/blood-2007-07-101311 (Pubitemid 351213430)
158. X Lu K Ohata Y Kondo J Luis Espinoza Z Qi S Nakao 2009 Hydroxyurea upregulates NKG2D ligand expression in myeloid leukemia cells synergistically with valproic acid and potentially enhances susceptibility of leukemic cells to natural killer cell-mediated cytolysis Cancer Sci 10.1111/j.1349-7006.2009. 01439.x
159. S Gasser S Orsulic EJ Brown DH Raulet 2005 The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 436 7054 1186 1190 10.1038/nature03884 1:CAS:528:DC%2BD2MXovVOgtr4%3D 15995699 10.1038/nature03884 (Pubitemid 41232299)
160. DS Ritchie H Quach K Fielding P Neeson 2010 Drug-mediated and cellular immunotherapy in multiple myeloma Immunotherapy 2 2 243 255 10.2217/imt.10.9 1:CAS:528:DC%2BC3cXivVCjsrc%3D 20635931 10.2217/imt.10.9
161. H Quach D Ritchie AK Stewart P Neeson S Harrison MJ Smyth HM Prince 2010 Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma Leukemia 24 1 22 32 10.1038/leu.2009.236 1:CAS:528:DC%2BC3cXltlejsg%3D%3D 19907437 10.1038/leu.2009.236
162. W Song Y-T Tai Z Tian T Hideshima D Chauhan P Nanjappa M Exley K Anderson N Munshi 2009 HDAC inhibition by LBH589 affects phenotype and function of human dendritic cells ASH Annu Meet Abstr 114 22 1646 EP -
163. A Nencioni J Beck D Werth F Grünebach F Patrone A Ballestrero P Brossart 2007 Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity Clin Cancer Res 13 13 3933 3941 10.1158/1078-0432.CCR-06-2903 1:CAS:528:DC%2BD2sXntFymt70%3D 17606727 10.1158/1078-0432.CCR-06-2903 (Pubitemid 47037601)
164. P Reddy Y Sun T Toubai R Duran-Struuck SG Clouthier E Weisiger Y Maeda I Tawara O Krijanovski E Gatza C Liu C Malter P Mascagni CA Dinarello JLM Ferrara 2008 Histone deacetylase inhibition modulates indoleamine 2, 3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice J Clin Invest 118 7 2562 2573 10.1172/JCI34712 1:CAS:528:DC%2BD1cXot1Ontbs%3D 18568076
165. BF Skinnider 2002 The role of cytokines in classical Hodgkin lymphoma Blood 99 12 4283 4297 10.1182/blood-2002-01-0099 1:CAS:528:DC%2BD38XksFGlu74%3D 12036854 10.1182/blood-2002-01-0099 (Pubitemid 34627193)
166. Dickinson M, Ritchie D, Deangelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Miles Prince H (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol:1-5. doi: 10.1111/j.1365-2141.2009.07837.x
167. L Wang R Tao WW Hancock 2009 Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance Immunol Cell Biol 87 3 195 202 10.1038/icb.2008.106 1:CAS:528: DC%2BD1MXjtlSqtb0%3D 19172156 10.1038/icb.2008.106
168. JL Lucas P Mirshahpanah E Haas-Stapleton K Asadullah TM Zollner RP Numerof 2009 Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors Cell Immunol 257 1-2 97 104 10.1016/j.cellimm.2009.03.004 1:CAS:528:DC%2BD1MXltVCru7k%3D 19358983 10.1016/j.cellimm.2009.03.004
169. J Johnson A Pahuja M Graham B Hering WW Hancock P Bansal-Pakala 2008 Effects of histone deacetylase inhibitor SAHA on effector and FOXP3∈+∈regulatory T cells in rhesus macaques Transplant Proc 40 2 459 461 10.1016/j.transproceed.2008.01.039 1:CAS:528:DC%2BD1cXktVCgt7s%3D 18374101 10.1016/j.transproceed.2008.01.039 (Pubitemid 351419219)
170. R Tao EF de Zoeten E Ozkaynak C Chen L Wang PM Porrett B Li LA Turka EN Olson MI Greene AD Wells WW Hancock 2007 Deacetylase inhibition promotes the generation and function of regulatory T cells Nat Med 13 11 1299 1307 10.1038/nm1652 1:CAS:528:DC%2BD2sXht1Kmtr3E 17922010 10.1038/nm1652 (Pubitemid 350073591)
171. F Ghiringhelli C Ménard F Martin L Zitvogel 2006 The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression Immunol Rev 214 229 238 10.1111/j.1600-065X.2006.00445.x 1:CAS:528:DC%2BD28XhtlClsrzJ 17100888 10.1111/j.1600-065X.2006.00445.x (Pubitemid 44707914)
172. RH Prabhala P Neri JE Bae P Tassone MA Shammas CK Allam JF Daley D Chauhan E Blanchard HS Thatte KC Anderson NC Munshi 2006 Dysfunctional T regulatory cells in multiple myeloma Blood 107 1 301 304 10.1182/blood-2005-08- 3101 1:CAS:528:DC%2BD28XhsVGltg%3D%3D 16150935 10.1182/blood-2005-08-3101 (Pubitemid 43053555)
173. PCJ Janson ME Winerdal O Winqvist 2009 At the crossroads of T helper lineage commitment-Epigenetics points the way Biochim Biophys Acta 1790 9 906 919 10.1016/j.bbagen.2008.12.003 1:CAS:528:DC%2BD1MXhtVSns7zK 19162128
174. J van Loosdregt Y Vercoulen T Guichelaar YYJ Gent JM Beekman O van Beekum AB Brenkman D-J Hijnen T Mutis E Kalkhoven BJ Prakken PJ Coffer 2010 Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization Blood 115 5 965 974 10.1182/blood-2009-02-207118 19996091 10.1182/blood-2009-02- 207118 1:CAS:528:DC%2BC3cXhvFOitrk%3D
175. CL Berger R Tigelaar J Cohen K Mariwalla J Trinh N Wang RL Edelson 2005 Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells Blood 105 4 1640 1647 10.1182/blood-2004-06-2181 1:CAS:528:DC%2BD2MXhsVChur0%3D 15514008 10.1182/blood-2004-06-2181 (Pubitemid 40223685)
176. WW Li M Hutnik G Gehr 2008 Antiangiogenesis in haematological malignancies Br J Haematol 143 5 622 631 10.1111/j.1365-2141.2008.07372.x 19036013 10.1111/j.1365-2141.2008.07372.x
177. L Ellis H Hammers R Pili 2009 Targeting tumor angiogenesis with histone deacetylase inhibitors Cancer Lett 280 2 145 153 10.1016/j.canlet.2008.11.012 1:CAS:528:DC%2BD1MXmsF2jt74%3D 19111391 10.1016/j.canlet.2008.11.012
178. C Urbich L Rössig D Kaluza M Potente J-N Boeckel A Knau F Diehl J-G Geng W-K Hofmann AM Zeiher S Dimmeler 2009 HDAC5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells Blood 113 22 5669 5679 10.1182/blood-2009-01-196485 1:CAS:528:DC%2BD1MXntVeqsr4%3D 19351956 10.1182/blood-2009-01-196485
179. MS Kim HJ Kwon YM Lee JH Baek JE Jang SW Lee EJ Moon HS Kim SK Lee HY Chung CW Kim KW Kim 2001 Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat Med 7 4 437 443 10.1038/86507 11283670 10.1038/86507 (Pubitemid 32298546)
180. CF Deroanne K Bonjean S Servotte L Devy A Colige N Clausse S Blacher E Verdin J-M Foidart BV Nusgens V Castronovo 2002 Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling Oncogene 21 3 427 436 10.1038/sj.onc.1205108 1:CAS:528:DC%2BD38XhtVygtL4%3D 11821955 10.1038/sj.onc.1205108
181. DZ Qian X Wang SK Kachhap Y Kato Y Wei L Zhang P Atadja R Pili 2004 The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 Cancer Res 64 18 6626 6634 10.1158/0008-5472.CAN-04-0540 1:CAS:528:DC%2BD2cXnsFOlu7w%3D 15374977 10.1158/0008-5472.CAN-04-0540 (Pubitemid 39297923)
182. S Kuljaca T Liu AEL Tee M Haber MD Norris T Dwarte GM Marshall 2007 Enhancing the anti-angiogenic action of histone deacetylase inhibitors Mol Cancer 6 68 10.1186/1476-4598-6-68 17958916 10.1186/1476-4598-6-68 1:CAS:528:DC%2BD2sXhtleqtrnL
183. DZ Qian Y Kato S Shabbeer Y Wei HMW Verheul B Salumbides T Sanni P Atadja R Pili 2006 Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589 Clin Cancer Res 12 2 634 642 10.1158/1078-0432.CCR-05-1132 1:CAS:528:DC%2BD28XmtlKgtA%3D%3D 16428510 10.1158/1078-0432.CCR-05-1132 (Pubitemid 43166159)
184. HJ Kwon MS Kim MJ Kim H Nakajima K-W Kim 2002 Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis Int J Cancer 97 3 290 296 1:CAS:528:DC%2BD38XhvVWlsQ%3D%3D 11774279 10.1002/ijc.1602 (Pubitemid 34049018)
185. M Medinger K Mross 2010 Clinical trials with anti-angiogenic agents in hematological malignancies J Angiogenes Res 2 10 10.1186/2040-2384-2-10 20569499 10.1186/2040-2384-2-10 1:CAS:528:DC%2BC3cXos12lsbs%3D
186. AB Aurora D Biyashev Y Mirochnik TA Zaichuk C Sánchez-Martinez M-A Renault D Losordo OV Volpert 2010 NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement Blood 116 3 475 484 10.1182/blood-2009-07-232132 1:CAS:528:DC%2BC3cXhtVejt7jI 20203265 10.1182/blood-2009-07-232132
187. J Wolf D Siegel J Matous S Lonial H Goldschmidt S Schmitt R Vij M De Malgalhaes-Silverman R Abonour M Jalaluddin M Li K Hazell P Bourquelot M-V Mateos K Anderson A Spencer J-L Harousseau J Blade 2008 A phase II study of oral panobinostat (LBH589) in adult patients with advanced refractory multiple myeloma ASH Annu Meet Abstr 112 11 2774 EP -
188. HMW Verheul B Salumbides K Van Erp H Hammers DZ Qian T Sanni P Atadja R Pili 2008 Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors Clin Cancer Res 14 11 3589 3597 10.1158/1078-0432.CCR-07-4306 1:CAS:528: DC%2BD1cXmslygt7s%3D 18519793 10.1158/1078-0432.CCR-07-4306
189. SJ Altschuler LF Wu 2010 Cellular heterogeneity: do differences make a difference? Cell 141 4 559 563 10.1016/j.cell.2010.04.033 1:CAS:528: DC%2BC3cXms1ehurc%3D 20478246 10.1016/j.cell.2010.04.033
190. A Trumpp OD Wiestler 2008 Mechanisms of disease: cancer stem cells-targeting the evil twin Nat Clin Prac Oncol 5 6 337 347 10.1038/ncponc1110 1:CAS:528:DC%2BD1cXmsFCgurc%3D (Pubitemid 351780950)
191. M Shackleton 2010 Normal stem cells and cancer stem cells: similar and different Semin Cancer Biol 20 2 85 92 10.1016/j.semcancer.2010.04.002 1:CAS:528:DC%2BC3cXnvVyhurc%3D 20435143 10.1016/j.semcancer.2010.04.002
192. T Reya SJ Morrison MF Clarke IL Weissman 2001 Stem cells, cancer, and cancer stem cells Nature 414 6859 105 111 10.1038/35102167 1:CAS:528: DC%2BD3MXot1ahs7c%3D 11689955 10.1038/35102167 (Pubitemid 33041634)
193. T Lin RJ Jones W Matsui 2009 Cancer stem cells: relevance to SCT Bone Marrow Transplant 43 7 517 523 10.1038/bmt.2009.19 1:STN:280: DC%2BD1M3mtlWqtg%3D%3D 19234507 10.1038/bmt.2009.19
194. W Matsui Q Wang JP Barber S Brennan BD Smith I Borrello I McNiece L Lin RF Ambinder C Peacock DN Watkins CA Huff RJ Jones 2008 Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance Cancer Res 68 1 190 197 10.1158/0008-5472.CAN-07-3096 1:CAS:528:DC%2BD1cXoslSi 18172311 10.1158/0008-5472.CAN-07-3096 (Pubitemid 351380120)
195. RJ Jones WH Matsui BD Smith 2004 Cancer stem cells: are we missing the target? J Natl Cancer Inst 96 8 583 585 15100335 10.1093/jnci/djh095
196. CD Peacock Q Wang GS Gesell IM Corcoran-Schwartz E Jones J Kim WL Devereux JT Rhodes CA Huff PA Beachy DN Watkins W Matsui 2007 Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma Proc Natl Acad Sci USA 104 10 4048 4053 10.1073/pnas.0611682104 1:CAS:528:DC%2BD2sXjt12gsbs%3D 17360475 10.1073/pnas.0611682104 (Pubitemid 47181576)
197. SV Sharma DY Lee B Li MP Quinlan F Takahashi S Maheswaran U Mcdermott N Azizian L Zou MA Fischbach K-K Wong K Brandstetter B Wittner S Ramaswamy M Classon J Settleman 2010 A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations Cell 141 1 69 80 10.1016/j.cell.2010.02.027 1:CAS:528:DC%2BC3cXlsVSgtb8%3D 20371346 10.1016/j.cell.2010.02.027
198. S Minucci C Nervi F Lo Coco PG Pelicci 2001 Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 20 24 3110 3115 10.1038/sj.onc.1204336 1:CAS:528: DC%2BD3MXks1Glurc%3D 11420727 10.1038/sj.onc.1204336 (Pubitemid 32553566)
199. F Grignani S De Matteis C Nervi L Tomassoni V Gelmetti M Cioce M Fanelli M Ruthardt FF Ferrara I Zamir C Seiser F Grignani MA Lazar S Minucci PG Pelicci 1998 Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia Nature 391 6669 815 818 10.1038/35901 1:CAS:528:DyaK1cXhtlCisrs%3D 9486655 10.1038/35901 (Pubitemid 28099683)
200. RJ Lin L Nagy S Inoue W Shao WH Miller RM Evans 1998 Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391 6669 811 814 10.1038/35895 1:CAS:528:DyaK1cXhtlCisr4%3D 9486654 10.1038/35895 (Pubitemid 28099682)
201. LZ He T Tolentino P Grayson S Zhong RP Warrell RA Rifkind PA Marks VM Richon PP Pandolfi 2001 Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia J Clin Invest 108 9 1321 1330 10.1172/JCI11537 1:CAS:528:DC%2BD3MXot12kt7Y%3D 11696577
202. RP Warrell LZ He V Richon E Calleja PP Pandolfi 1998 Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J Natl Cancer Inst 90 21 1621 1625 1:CAS:528:DyaK1cXnsVCgt7k%3D 9811311 10.1093/jnci/90.21.1621
203. DC Zhou SH Kim W Ding C Schultz RP Warrell Jr RE Gallagher 2002 Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo Blood 99 4 1356 1363 1:CAS:528:DC%2BD38XhtlWqtrk%3D 11830487 10.1182/blood.V99.4.1356 (Pubitemid 34547092)
204. I Kitabayashi A Yokoyama K Shimizu M Ohki 1998 Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation EMBO J 17 11 2994 3004 10.1093/emboj/17.11.2994 1:CAS:528:DyaK1cXjvFejtbo%3D 9606182 10.1093/emboj/17.11.2994 (Pubitemid 28254372)
205. J Wang T Hoshino RL Redner S Kajigaya JM Liu 1998 ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex Proc Natl Acad Sci USA 95 18 10860 10865 1:CAS:528:DyaK1cXlvFWgtrw%3D 9724795 10.1073/pnas.95.18.10860 (Pubitemid 28413159)
206. F Fazi G Zardo V Gelmetti L Travaglini A Ciolfi L Di Croce A Rosa I Bozzoni F Grignani F Lo-Coco PG Pelicci C Nervi 2007 Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia Blood 109 10 4432 4440 10.1182/blood-2006-09-045781 1:CAS:528:DC%2BD2sXls1amsLY%3D 17244680 10.1182/blood-2006-09-045781 (Pubitemid 46743413)
207. Y Tabe L Jin R Contractor D Gold P Ruvolo S Radke Y Xu Y Tsutusmi-Ishii K Miyake N Miyake S Kondo A Ohsaka I Nagaoka M Andreeff M Konopleva 2007 Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1 Cell Death Differ 14 8 1443 1456 10.1038/sj.cdd.4402139 1:CAS:528:DC%2BD2sXnvVemt7k%3D 17464329 10.1038/sj.cdd.4402139 (Pubitemid 47086732)
208. J Wang Y Saunthararajah RL Redner JM Liu 1999 Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells Cancer Res 59 12 2766 2769 1:CAS:528:DyaK1MXktVOktbs%3D 10383127
209. OM Odenike S Alkan D Sher JE Godwin D Huo SJ Brandt M Green J Xie Y Zhang DH Vesole P Stiff J Wright RA Larson W Stock 2008 Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia Clin Cancer Res 14 21 7095 7101 10.1158/1078-0432.CCR-08-1007 1:CAS:528:DC%2BD1cXhtlens7fF 18981008 10.1158/1078-0432.CCR-08-1007
210. ZB Xia M Anderson MO Diaz NJ Zeleznik-Le 2003 MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein Proc Natl Acad Sci USA 100 14 8342 8347 10.1073/pnas.1436338100 1:CAS:528:DC%2BD3sXlsFGnt7o%3D 12829790 10.1073/pnas.1436338100 (Pubitemid 36842547)
211. AV Krivtsov SA Armstrong 2007 MLL translocations, histone modifications and leukaemia stem-cell development Nat Rev Cancer 7 11 823 833 10.1038/nrc2253 1:CAS:528:DC%2BD2sXht1Wgsb%2FJ 17957188 10.1038/nrc2253 (Pubitemid 350006257)
212. OM Sobulo J Borrow R Tomek S Reshmi A Harden B Schlegelberger D Housman NA Doggett JD Rowley NJ Zeleznik-Le 1997 MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3) Proc Natl Acad Sci USA 94 16 8732 8737 1:CAS:528: DyaK2sXltlWhsbs%3D 9238046 10.1073/pnas.94.16.8732 (Pubitemid 27335108)
213. MJ Thirman HJ Gill RC Burnett D Mbangkollo NR McCabe H Kobayashi S Ziemin-van der Poel Y Kaneko R Morgan AA Sandberg, et al. 1993 Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations N Engl J Med 329 13 909 914 1:CAS:528: DyaK3sXmsVKqsL8%3D 8361504 10.1056/NEJM199309233291302 (Pubitemid 23275271)
214. RK Slany 2009 The molecular biology of mixed lineage leukemia Haematologica 94 7 984 993 10.3324/haematol.2008.002436 1:CAS:528: DC%2BD1MXhtVGitrrK 19535349 10.3324/haematol.2008.002436
215. M Liedtke ML Cleary 2009 Therapeutic targeting of MLL Blood 113 24 6061 6068 10.1182/blood-2008-12-197061 1:CAS:528:DC%2BD1MXnslSmuro%3D 19289854 10.1182/blood-2008-12-197061
216. R Tonelli R Sartini R Fronza F Freccero M Franzoni D Dongiovanni M Ballarini S Ferrari M D'Apolito G Di Cola G Capranico A Khobta R Campanini P Paolucci S Minucci A Pession 2006 G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent Leukemia 20 7 1307 1310 10.1038/sj.leu.2404221 1:CAS:528:DC%2BD28XlvFGjtLk%3D 16617320 10.1038/sj.leu.2404221 (Pubitemid 43905841)
217. Burbury KL, Bishton MJ, Johnstone RW, Dickinson M, Szer J, Prince HM (2010) Sustained complete cytogenetic remission in MLL-aberrant leukemia following treatment with a Histone Deacetylase (HDAC) inhibitor (HDACi). Ann Hematol In Press. doi: 10.1007/s00277-010-1099-6
218. HM Prince MJ Bishton SJ Harrison 2009 Clinical studies of histone deacetylase inhibitors Clin Cancer Res 15 12 3958 3969 10.1158/1078-0432.ccr-08- 2785 1:CAS:528:DC%2BD1MXntlOis78%3D 19509172 10.1158/1078-0432.CCR-08-2785
219. M Bots RW Johnstone 2009 Rational combinations using HDAC inhibitors Clin Cancer Res 15 12 3970 3977 10.1158/1078-0432.CCR-08-2786 1:CAS:528: DC%2BD1MXntlOis7w%3D 19509171 10.1158/1078-0432.CCR-08-2786
220. AR Guardiola T-P Yao 2002 Molecular cloning and characterization of a novel histone deacetylase HDAC10 J Biol Chem 277 5 3350 3356 10.1074/jbc.M109861200 1:CAS:528:DC%2BD38XhtVaksbg%3D 11726666 10.1074/jbc.M109861200 (Pubitemid 34953202)